Amicus Therapeutics to Host FDA Update Conference Call Today

CRANBURY, N.J., Oct. 2, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, announced that in follow-up to the press release issued earlier today about the regulatory update from the U.S. Food and Drug Administration (FDA) on the oral small molecule pharmacological chaperone migalastat, Amicus is hosting a conference call and live audio webcast Friday, October 2, 2015 at 11:00 a.m. ET.

The call will be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team. Interested participants and investors may access the conference call at 11:00 a.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international).

A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at, and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software.

A telephonic replay of the call will be available for seven days beginning at 2:00 pm ET on October 2, 2015. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participate code 54594506.

About Amicus Therapeutics

Amicus Therapeutics, Inc. (Nasdaq:FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus' lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as next-generation enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and MPS I.


CONTACT: Investors/Media: Amicus Therapeutics Chip Baird Chief Financial Officer (609) 662-5022 Media: Pure Communications Katie Engleman (910) 509-3977

Source:Amicus Therapeutics, Inc.